Point-of-Care Molecular Diagnostics Market Size, Share, Growth Analysis, By Technology(PCR-based, Genetic Sequencing-based, Hybridization-based, Microarray-based), By Application Type(Infectious Diseases, HIV POC, Clostridium difficile POC, HBV POC), By Location(OTC, POC), By End-use(Decentralized Labs, Hospitals, Home-care, Assisted Living Health Care Facilities), By Regional(North America, Europe, Asia Pacific, Latin America) - Industry Forecast 2024-2031

Point-of-Care Molecular Diagnostics Market Competitive Landscape

To understand the competitive landscape, we are analyzing key Point-of-Care Molecular Diagnostics Market vendors in the market. To understand the competitive rivalry, we are comparing the revenue, expenses, resources, product portfolio, region coverage, market share, key initiatives, product launches, and any news related to the Point-of-Care Molecular Diagnostics Market.

To validate our hypothesis and validate our findings on the market ecosystem, we are also conducting a detailed porter's five forces analysis. Competitive Rivalry, Supplier Power, Buyer Power, Threat of Substitution, and Threat of New Entry each force is analyzed by various parameters governing those forces.

Key Players Covered in the Report:

• Abbott
• Bayer AG
• F. Hoffmann-La Roche AG
• Nova Biomedical
• QIAGEN
• Nipro Diagnostics
• Danaher
• Bio-Rad Laboratories, Inc.
• bioMérieux
• Agilent Technologies, Inc.
• Abaxis
• OraSure Technologies